Disease · MONDO_0005075

thyroid gland papillary carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thyroid gland papillary carcinoma. Diseases, record MONDO_0005075. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005075

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thyroid gland papillary carcinoma; Open Targets
Open Targets ID: MONDO_0005075; Open Targets
Other names: PTC, papillary cancer of the thyroid, papillary cancer of the thyroid gland, papillary cancer of thyroid, papillary cancer of thyroid gland, papillary carcinoma of the thyroid, papillary carcinoma of the thyroid gland, papillary carcinoma of thyroid, papillary carcinoma of thyroid gland, papillary thyroid cancer, papillary thyroid carcinoma, papillary thyroid gland carcinoma, thyroid gland papillary cancer, thyroid papillary carcinoma; Open Targets
Disease Ontology: DOID:3969; Disease Ontology
NCI Thesaurus: C4035; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 37 drugs, from ClinicalTrials.gov; Open Targets

Drugs37

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IODINE	CHEMBL1201225	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ENTRECTINIB	CHEMBL1983268	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RIVOCERANIB	CHEMBL3186534	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SORAFENIB	CHEMBL1336	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 37

See all 37 drugs

Targets170

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	5	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
RET	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET	5	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ALK	ALK tyrosine kinase receptor	2	ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor	Phase 2	https://conductscience.org/library/genes/238	Drugs and targets
CCDC6	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET	2	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/8030	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets

1 to 10 of 170

See all 170 targets

Trials32

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00537095	Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer	Phase 2	164	2011-07-08	Thyroid Neoplasms	VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT01677741	A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects	Phase 1/2	85	2021-11-24	Neoplasms, Brain	DABRAFENIB	Its record names the disease	ClinicalTrials.gov
NCT01286753	A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation	Phase 2	51	2016-09-07	Neoplasms	VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00559949	Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine	Phase 2	39	2017-01-30	Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma	SELUMETINIB	Its record names the disease	ClinicalTrials.gov
NCT00923481	A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	Phase 2	37	2012-08-29	Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell	FOSTAMATINIB DISODIUM	Its record names the disease	ClinicalTrials.gov
NCT00251316	Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer	Phase 2	34	2012-12-27	Thyroid Cancer, Differentiated Thyroid Carcinoma	LITHIUM CARBONATE	Its record names the disease	ClinicalTrials.gov
NCT00287287	REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas	Phase 2	25	2020-06-12	Thyroid Neoplasms	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00104871	Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy	Phase 2	24	2014-06-25	Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer	BORTEZOMIB	Its record names the disease	ClinicalTrials.gov
NCT01502410	Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer	Phase 2	20	2015-05-15	Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Thyroid Cancer, Recurrent Wilms Tumor and Other Childhood Kidney Tumors	SORAFENIB TOSYLATE	Its record names the disease	ClinicalTrials.gov
NCT00085293	Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131	Phase 2	12	2014-09-01	Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer	DECITABINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 32

See all 32 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ZD6474 vs PLACEBO: Objective Response Rate	6 of 72	4 of 73	145	NCT00537095	Trial comparisons
ZD6474 vs PLACEBO: Time to Death	19 of 72	21 of 73	145	NCT00537095	Trial comparisons
ZD6474 vs PLACEBO: Disease Control Rate at 6 Months	41 of 72	31 of 73	145	NCT00537095	Trial comparisons
TKI Naive vs TKI Experienced: serious adverse events	16 of 26	18 of 25	51	NCT01286753	Trial comparisons
Lithium Carbonate vs Placebo: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year.	10 of 15	10 of 14	29	NCT00251316	Trial comparisons
Lithium Carbonate vs Placebo: serious adverse events	0 of 15	1 of 14	29	NCT00251316	Trial comparisons
Group 1 Relapsed/Refractory Rhabdomyosarcoma vs Group 2 Relapsed/Refractory Wilms Tumor: serious adverse events	4 of 10	3 of 10	20	NCT01502410	Trial comparisons

Papers from its trials24

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32182156	RESULT	1	PubMed
25549723	RESULT	1	PubMed
40304938	DERIVED	1	PubMed
39549678	DERIVED	1	PubMed
37549532	DERIVED	1	PubMed
36884302	DERIVED	1	PubMed
35767182	DERIVED	1	PubMed
34509954	DERIVED	1	PubMed
34427452	DERIVED	1	PubMed
33847874	DERIVED	1	PubMed

1 to 10 of 24

See all 24 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005075

GET https://conductscience.org/api/diseases/v1/MONDO_0005075/drugs?page=2

API reference For AI assistants